Topical 4-OHA Prodrug for ERβ-Positive Breast Tumor Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for breast cancer, particularly ERβ-positive breast cancer, often require surgical removal of the breast and have limitations such as incomplete inhibition of tumor growth, rapid metabolization of treatments, and unsatisfactory effects on triple-negative breast cancer, which lacks estrogen receptors and is aggressive.
Innovation Solution
The use of 4-hydroxyandrost-4-ene-3,17-dione (4-OHA) as a prodrug, applied topically, which metabolizes into compounds with high affinity for ERβ, potentially binding to AR, reducing tumor size and inhibiting cell proliferation, allowing for breast-conserving surgery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If surgical removal of the breast is performed, then complete tumor removal is achieved, but the patient loses the breast and suffers from high metastatic potential
Solution Approach 1:
The patent applies preliminary action by using topical 4-OHA treatment before surgery to reduce tumor size and inhibit metastatic potential. The prodrug is applied topically to the breast tissue prior to surgical intervention, allowing it to metabolize and exert anti-proliferative effects on the tumor, thereby preparing the tissue for less aggressive surgical removal while reducing the risk of metastasis
Solution Approach 2:
The patent uses 4-OHA as an intermediary substance that mediates between the tumor and the surgical intervention. This prodrug metabolizes to compounds that selectively bind to ERβ receptors in tumor cells, acting as a bridge that inhibits tumor growth and metastatic potential without requiring complete surgical removal of the breast tissue
2Reliability
If conventional aromatase inhibitors are used, then estrogen production is blocked, but the treatment has rapid metabolization and incomplete inhibition of tumor growth
Solution Approach 1:
The patent changes the parameter of drug delivery from systemic administration to topical application. By applying 4-OHA topically to the breast tissue, the prodrug achieves localized high concentrations that penetrate the skin and target ERβ-positive tumor cells directly, thereby extending the effective duration of action and reducing rapid systemic metabolization
Solution Approach 2:
The patent introduces 4-OHA as a prodrug intermediary that metabolizes locally in the breast tissue to active compounds with high affinity for ERβ. This intermediary approach allows sustained local action without rapid systemic clearance, effectively extending the duration of estrogen production blocking at the tumor site
3Reliability
If Tamoxifen is used, then estrogen receptor binding is achieved, but the treatment has tachyphylaxy and estrogen-like side effects limiting long-term use
Solution Approach 1:
The patent applies local quality by using topical administration of 4-OHA to achieve high local concentrations at the tumor site while minimizing systemic circulation. This localized delivery reduces the development of tachyphylaxy and limits exposure to estrogen-like side effects, thereby enabling longer-term therapy without the limitations seen with systemic Tamoxifen
Solution Approach 2:
The patent changes the delivery parameter from oral/systemic to topical application, which fundamentally alters the pharmacokinetic profile. This results in sustained local action with reduced systemic side effects and delayed onset of tachyphylaxy, extending the feasible duration of therapy
4Speed
If topical application is used, then enhanced skin penetration is achieved, but selective binding to ERβ must be maintained without affecting ERα
Solution Approach 1:
The patent changes the chemical parameter of the prodrug structure (4-OHA) to produce metabolites with specific molecular characteristics that enable both rapid skin penetration and selective ERβ binding. The prodrug design incorporates functional groups that facilitate dermal absorption while the metabolized products exhibit high affinity and selectivity for ERβ over ERα through specific receptor-interaction properties
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Significant reduction in breast tumor volume, enabling breast-conserving surgery, with the prodrug and its metabolites showing enhanced skin penetration and selective binding to ERβ, effectively inhibiting tumor growth even in AR-negative and ERα-negative breast cancers like TNBC.
Implementation Method 1
The steroid compound 4-hydroxyandrost-4-ene-3,17-dione (4-OHA) as a prodrug... which metabolizes into compounds with high affinity for ERβ
Implementation Method 2
showing enhanced skin penetration and selective binding to ERβ, effectively inhibiting tumor growth
Implementation Method 3
applied topically... showing enhanced skin penetration
Data Source
AI summary
The present invention relates to the field of medicine, and refers to the steroid compound 4-hydroxyandrost-4-ene-3,17-dione (4-OHA) or ester thereof, as a prodrug for use in the treatment of a patient suffering from estrogen-receptor β (ERβ) positive breast tumour. The present invention further relates to a pharmaceutical composition comprising said steroid compound for topical application, and the use of said steroid compound in a pre-surgical topical treatment of ERβ-positive breast cancer tissue.